Erica Stuart

Erica Stuart

Auto-generated profile, based on publicly available information

Erica Stuart

Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2023 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
HLHeather H. C. Lau
Heather H. C. Lau
IMIván Martínez-Valbuena
Iván Martínez-Valbuena
RSRaphaella W. L. So
Raphaella W. L. So
SMSurabhi Mehra
Surabhi Mehra
NSNicholas R. G. Silver
Nicholas R. G. Silver
JWJoel C. Watts
Joel C. Watts
Unique strains of α-synuclein aggregates have been postulated to underlie the spectrum of clinical and pathological presentations seen across the synucleinopathies. Whereas multiple system atrophy (MSA) is associated with a predominance of oligodendroglial α-synuclein inclusions, α-synuclein aggregates in Parkinson’s disease (PD) preferentially accumulate in neurons. The G51D mutation in the SNCA gene encoding α-synuclein causes an aggressive, early-onset form of PD that exhibits clinical and neuropathological traits reminiscent of both PD and MSA. To assess the strain characteristics of G51D PD α-synuclein aggregates, we performed propagation studies in M83 transgenic mice by intracerebrally inoculating patient brain extracts. The properties of the induced α-synuclein aggregates in the brains of injected mice were examined using immunohistochemistry, a conformational stability assay, and by performing α-synuclein seed amplification assays. Unlike MSA-injected mice, which developed a progressive motor phenotype, G51D PD-inoculated animals remained free of overt neurological illness for up to 18 months post-inoculation. However, a subclinical synucleinopathy was present in G51D PD-inoculated mice, characterized by the accumulation of α-synuclein aggregates in restricted regions of the brain. The induced α-synuclein aggregates in G51D PD-injected mice exhibited distinct properties in a seed amplification assay and were much more stable than those present in mice injected with MSA extract, which mirrored the differences observed between human MSA and G51D PD brain samples. These results suggest that the G51D SNCA mutation specifies the formation of a slowly propagating α-synuclein strain that more closely resembles α-synuclein aggregates associated with PD than MSA.

10 May 2021 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
ARAlejandro Iván Ruiz Riquelme
Alejandro Iván Ruiz Riquelme
AMAlison Mao
Alison Mao
MBMarim M. Barghash
Marim M. Barghash
HLHeather H. C. Lau
Heather H. C. Lau
ESErica Stuart
Erica Stuart
JWJoel C. Watts
Joel C. Watts
When injected into genetically modified mice, aggregates of the amyloid-β (Aβ) peptide from the brains of Alzheimer’s disease (AD) patients or transgenic AD mouse models seed cerebral Aβ deposition in a prion-like fashion. Within the brain, Aβ exists as a pool of distinct C-terminal variants with lengths ranging from 37 to 43 amino acids, yet the relative contribution of individual C-terminal Aβ variants to the seeding behavior of Aβ aggregates remains unknown. Here, we have investigated the relative seeding activities of Aβ aggregates composed exclusively of recombinant Aβ38, Aβ40, Aβ42, or Aβ43. Cerebral Aβ42 levels were not increased in AppNL−F knock-in mice injected with Aβ38 or Aβ40 aggregates and were only increased in a subset of mice injected with Aβ42 aggregates. In contrast, significant accumulation of Aβ42 was observed in the brains of all mice inoculated with Aβ43 aggregates, and the extent of Aβ42 induction was comparable to that in mice injected with brain-derived Aβ seeds. Mice inoculated with Aβ43 aggregates exhibited a distinct pattern of cerebral Aβ pathology compared to mice injected with brain-derived Aβ aggregates, suggesting that recombinant Aβ43 may polymerize into a unique strain. Our results indicate that aggregates containing longer Aβ C-terminal variants are more potent inducers of cerebral Aβ deposition and highlight the potential role of Aβ43 seeds as a crucial factor in the initial stages of Aβ pathology in AD.

7 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RSRaphaella W.L. So
Raphaella W.L. So
BFBenedikt Frieg
Benedikt Frieg
JCJosé D. Camino
José D. Camino
NSNicholas R.G. Silver
Nicholas R.G. Silver
AMAlison Mao
Alison Mao
JWJoel C. Watts
Joel C. Watts
The existence of α-synuclein conformational strains provides a potential explanation for the clinical and pathological differences among synucleinopathies such as Parkinson’s disease and multiple system atrophy. However, how distinct α-synuclein strains are formed in vivo remains unknown. Here, we examined whether unique strains of self-propagating α-synuclein aggregates can arise within a consistent molecular environment. Unexpectedly, we observed conformational heterogeneity between individual preparations of α-synuclein pre-formed fibrils (PFFs) generated by polymerizing recombinant wild-type or A53T-mutant human α-synuclein under identical conditions. Moreover, we found that α-synuclein aggregates formed spontaneously in the brains of a transgenic synucleinopathy mouse model were conformationally diverse, leading to the identification of three distinct disease subtypes. Propagation of putative PFF- and brain-derived α-synuclein strains in mice initiated several distinct synucleinopathies, characterized by differences in disease onset times, cerebral α-synuclein deposition patterns, and the conformational attributes of α-synuclein aggregates. The conformational diversity of α-synuclein aggregates across PFF preparations and between the brains of individual transgenic mice demonstrates that α-synuclein can spontaneously form multiple self-propagating strains within an identical environment both in vitro and in vivo . This suggests that stochastic misfolding into distinct aggregate structures drives the emergence of α-synuclein strains and implies that the intrinsic variability of common synucleinopathy research tools must be considered when designing and interpreting experiments.

14 August 2026 in Brain Pathology
Verified
Journal Article
Open access
PDF file
HLHeather H. C. Lau
Heather H. C. Lau
NSNicholas R. G. Silver
Nicholas R. G. Silver
SMSurabhi Mehra
Surabhi Mehra
RSRaphaella W. L. So
Raphaella W. L. So
LLLe Yao Li
Le Yao Li
JWJoel C. Watts
Joel C. Watts
Conformationally distinct “strains” of α‐synuclein aggregates are believed to contribute to the clinical and pathological diversity observed among synucleinopathies such as multiple system atrophy (MSA) and Parkinson's disease. Cases of MSA can be classified into two distinct subtypes: the cerebellar variant, MSA‐C, and the parkinsonian variant, MSA‐P, as determined by differences in their clinical and/or neuropathological presentations. To assess whether distinct α‐synuclein strains may be present in individuals with MSA‐C versus MSA‐P, we characterized the conformational and seeding properties of α‐synuclein aggregates in various brain regions from MSA‐C and MSA‐P patients and performed propagation studies in M83 transgenic mice. Biochemical fingerprinting of α‐synuclein aggregates using limited proteolysis and a conformational stability assay failed to reveal differences between MSA‐C and MSA‐P either before or after propagation in mice. Similarly, using brain extracts from either MSA patients or MSA‐inoculated mice, MSA‐C and MSA‐P α‐synuclein aggregates exhibited indistinguishable seeding attributes in a seed amplification assay. Finally, no differences were observed in either the kinetics of disease progression or the extent of cerebral α‐synuclein deposition in M83 mice inoculated with either MSA‐C or MSA‐P, regardless of the brain region from which the injected α‐synuclein aggregates were derived. These results suggest that MSA subtypes are unlikely to arise because of distinct α‐synuclein strains. Instead, our findings support a model in which the same α‐synuclein strain initially forms in different brain regions, leading to differences in disease manifestation.


28 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
GAGenki Amano
Genki Amano
HAHamza Arshad
Hamza Arshad
SMSurabhi Mehra
Surabhi Mehra
MBMatthew E.C. Bourkas
Matthew E.C. Bourkas
ESErica Stuart
Erica Stuart
JWJoel C. Watts
Joel C. Watts
Mutations in the PRNP gene, which encodes the prion protein (PrP), cause genetic prion disease. However, how PRNP mutations lead to spontaneous prion formation remains poorly understood. Building off the observation that expression of mutant bank vole PrP (BVPrP) in mice causes spontaneous prion disease, we sought to identify early events in prion formation by expressing mutant BVPrP in cultured cells lacking endogenous PrP. Expression of D178N- and E200K-mutant, but not wild-type BVPrP, in CAD5-PrP -/- and N2a-PrP -/- cells generates an a lternatively m isfolded PrP species, which we term PrP AM , that is detergent-insoluble and resistant to digestion with the protease thermolysin. PrP AM is also present in the brains of young, asymptomatic knock-in mice expressing mutant BVPrP. However, PrP AM does not appear to be a direct precursor of prions since 1) the prion disease-protective G127V substitution enhances PrP AM levels when coupled with the D178N or E200K mutations; 2) small molecule anti-prion drugs fail to reduce PrP AM accumulation in cells; 3) unlike cells expressing wild-type BVPrP, cells expressing D178N- or E200K-mutant BVPrP are largely resistant to infection with several prion strains; and 4) PrP AM -containing cell homogenate does not contain seeds that induce misfolding of wild-type BVPrP in either cells or the RT-QuIC assay. These results raise the possibility that prion disease-causing PRNP mutations initially generate a protective misfolded PrP species that is refractory to prion formation, which provides a potential explanation for why genetic prion diseases manifest later in life despite the presence of a mutation from birth.